Docetaxel-cisplatin-5FU (TCF) versus docetaxel-cisplatin (TC) versus epirubicin-cisplatin-5FU (ECF) as systemic treatment for advanced gastric carcinoma (AGC): A randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK)

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 4020-4020 ◽  
Author(s):  
A. D. Roth ◽  
R. Maibach ◽  
S. Falk ◽  
R. Stupp ◽  
P. Saletti ◽  
...  
Keyword(s):  
Cancer Research ◽  
Gastric Carcinoma ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Systemic Treatment ◽  
Clinical Cancer Research ◽  
Clinical Cancer ◽  
Advanced Gastric Carcinoma ◽  
Randomized Phase Ii

Docetaxel, Cisplatin, and Fluorouracil; Docetaxel and Cisplatin; and Epirubicin, Cisplatin, and Fluorouracil As Systemic Treatment for Advanced Gastric Carcinoma: A Randomized Phase II Trial of the Swiss Group for Clinical Cancer Research

2007 ◽  
Vol 25 (22) ◽  
pp. 3217-3223 ◽  
Author(s):  
Arnaud D. Roth ◽  
Nicola Fazio ◽  
Roger Stupp ◽  
Stephen Falk ◽  
Jürg Bernhard ◽  
...  
Keyword(s):  
Gastric Carcinoma ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Performance Status ◽  
Infectious Complications ◽  
Phase Iii ◽  
Survival Times ◽  
Clinical Cancer Research ◽  
Advanced Gastric Carcinoma ◽  
Randomized Phase Ii

PurposeThis randomized phase II trial evaluated two docetaxel-based regimens to see which would be most promising according to overall response rate (ORR) for comparison in a phase III trial with epirubicin-cisplatin-fluorouracil (ECF) as first-line advanced gastric cancer therapy.Patients and MethodsChemotherapy-naïve patients with measurable unresectable and/or metastatic gastric carcinoma, a performance status ≤ 1, and adequate hematologic, hepatic, and renal function randomly received ≤ eight 3-weekly cycles of ECF (epirubicin 50 mg/m2on day 1, cisplatin 60 mg/m2on day 1, and fluorouracil [FU] 200 mg/m2/d on days 1 to 21), TC (docetaxel initially 85 mg/m2on day 1 [later reduced to 75 mg/m2as a result of toxicity] and cisplatin 75 mg/m2on day 1), or TCF (TC plus FU 300 mg/m2/d on days 1 to 14). Study objectives included response (primary), survival, toxicity, and quality of life (QOL).ResultsORR was 25.0% (95% CI, 13% to 41%) for ECF, 18.5% (95% CI, 9% to 34%) for TC, and 36.6% (95% CI, 23% to 53%) for TCF (n = 119). Median overall survival times were 8.3, 11.0, and 10.4 months for ECF, TC, and TCF, respectively. Toxicity was acceptable, with one toxic death (TC arm). Grade 3 or 4 neutropenia occurred in more treatment cycles with docetaxel (TC, 49%; TCF, 57%; ECF, 34%). Global health status/QOL substantially improved with ECF and remained similar to baseline with both docetaxel regimens.ConclusionTime to response and ORR favor TCF over TC for further evaluation, particularly in the neoadjuvant setting. A trend towards increased myelosuppression and infectious complications with TCF versus TC or ECF was observed.

Phase II trial of trimetrexate for patients with advanced gastric carcinoma

Cancer ◽  
1999 ◽  
Vol 86 (4) ◽  
pp. 572-576 ◽  
Author(s):  
Ramesh K. Ramanathan ◽  
Stuart Lipsitz ◽  
Robert F. Asbury ◽  
Raman Qazi ◽  
Bernard R. Greenberg ◽  
...  
Keyword(s):  
Gastric Carcinoma ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Advanced Gastric Carcinoma
Sign in / Sign up

Export Citation Format

Share Document